XML 94 R1.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Cover Page - USD ($)
 12 Months Ended
Dec. 31, 2019
Feb. 14, 2020
Jun. 30, 2019
Cover page.      
Document Type 10-K    
Document Annual Report true    
Document Period End Date Dec. 31, 2019    
Document Transition Report false    
Entity File Number 001-36152    
Entity Registrant Name Aerie Pharmaceuticals, Inc.    
Entity Incorporation, State or Country Code DE    
Entity Tax Identification Number 20-3109565    
Entity Address, Address Line One 4301 Emperor Boulevard,    
Entity Address, Address Line Two Suite 400    
Entity Address, City or Town Durham,    
Entity Address, State or Province NC    
Entity Address, Postal Zip Code 27703    
City Area Code 919    
Local Phone Number 237-5300    
Title of 12(b) Security Common Stock, $0.001 par value per share    
Trading Symbol AERI    
Security Exchange Name NASDAQ    
Entity Well-known Seasoned Issuer Yes    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
Entity Filer Category Large Accelerated Filer    
Entity Small Business false    
Entity Emerging Growth Company false    
Entity Shell Company false    
Entity Public Float     $ 1,334,440,206
Entity Common Stock, Shares Outstanding   46,428,456  
Documents Incorporated by Reference
Portions of the registrant’s definitive proxy statement (the “Proxy Statement”) for the 2020 Annual Meeting of Stockholders are incorporated by reference into Part III of this Annual Report on Form 10-K. The Proxy Statement will be filed with the Securities and Exchange Commission (the “SEC”) within 120 days of the registrant’s fiscal year ended December 31, 2019.
    
Entity Central Index Key 0001337553    
Current Fiscal Year End Date --12-31    
Document Fiscal Year Focus 2019    
Document Fiscal Period Focus FY    
Amendment Flag false